Review





Similar Products

r21 malaria vaccine  (Serum Institute India)
86
Serum Institute India r21 malaria vaccine
R21 Malaria Vaccine, supplied by Serum Institute India, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/r21 malaria vaccine/product/Serum Institute India
Average 86 stars, based on 1 article reviews
r21 malaria vaccine - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
malaria vaccine evaluation  (Glaxo Smith)
86
Glaxo Smith malaria vaccine evaluation
Malaria Vaccine Evaluation, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/malaria vaccine evaluation/product/Glaxo Smith
Average 86 stars, based on 1 article reviews
malaria vaccine evaluation - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
malaria vaccine  (Glaxo Smith)
86
Glaxo Smith malaria vaccine
Malaria Vaccine, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/malaria vaccine/product/Glaxo Smith
Average 86 stars, based on 1 article reviews
malaria vaccine - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
blood stage malaria candidate vaccine r78c  (Novavax Inc)
86
Novavax Inc blood stage malaria candidate vaccine r78c
A) In vitro GIA against 3D7 clone P. falciparum using i) a pool of purified total IgG from <t>R78C/Matrix-M</t> healthy UK adult vaccinees tested at 6 mg/mL; ii) protein alone controls (CyRPA and RIPR) both at 5 µM; iii) a pool of anti-RIPR EGF (9-10)-CTD mAbs (RP.063, RP.064, RP.073 and RP.085) and a pool of anti-RIPR EGF (6) mAbs (RP.047 and RP.107), both at 1 mg/mL; and iv) combinations of test samples. B ) GIA of the purified total IgG from R78C vaccinees combined with CyRPA protein along with addition of either or both of the anti-RIPR mAb pools (all concentrations as in panel A). Grey bars show % GIA predicted by Bliss additivity (PBA) of the test combinations, and blue bars how the measured % GIA. C ) GIA of the purified total IgG from R78C vaccinees (without CyRPA protein) tested at 6, 3 or 1 mg/mL alone (red bars) or with addition of both of the anti-RIPR mAb pools (at a fixed total concentration of 2 mg/mL). Grey and blue bars indicate predicted and measured GIA as in panel B. Bars show mean, N = 2 independent replicates. D ) Cartoon summary of the proposed two-step mechanism for GIA mediated by anti-RIPR-Tail antibodies. left: the full P. falciparum PCRCR-complex binds to basigin-MCT1 complexes on the erythrocyte surface. Centre left: binding of anti-RIPR EGF (6-8) mAbs (orange) can lead to partial GIA. Centre right: anti-RIPR (9-10)-CTD mAbs (blue) or anti-CSS sdAbs (yellow) that block the RIPR-CSS binding interface are normally unable to access their epitopes and so invasion proceeds (no GIA). Right: Binding of anti-RIPR EGF (6-8) antibodies constrains RIPR-Tail conformational flexibility and disrupts the low affinity RIPR-CSS interaction. Exposure of the RIPR-CSS binding interface now enables binding of anti-RIPR (9-10)-CTD mAbs or anti-CSS sdAbs to their epitopes, thus blocking further RIPR-CSS interaction and synergistically enhancing GIA.
Blood Stage Malaria Candidate Vaccine R78c, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/blood stage malaria candidate vaccine r78c/product/Novavax Inc
Average 86 stars, based on 1 article reviews
blood stage malaria candidate vaccine r78c - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
candidate malaria vaccine  (Glaxo Smith)
86
Glaxo Smith candidate malaria vaccine
A) In vitro GIA against 3D7 clone P. falciparum using i) a pool of purified total IgG from <t>R78C/Matrix-M</t> healthy UK adult vaccinees tested at 6 mg/mL; ii) protein alone controls (CyRPA and RIPR) both at 5 µM; iii) a pool of anti-RIPR EGF (9-10)-CTD mAbs (RP.063, RP.064, RP.073 and RP.085) and a pool of anti-RIPR EGF (6) mAbs (RP.047 and RP.107), both at 1 mg/mL; and iv) combinations of test samples. B ) GIA of the purified total IgG from R78C vaccinees combined with CyRPA protein along with addition of either or both of the anti-RIPR mAb pools (all concentrations as in panel A). Grey bars show % GIA predicted by Bliss additivity (PBA) of the test combinations, and blue bars how the measured % GIA. C ) GIA of the purified total IgG from R78C vaccinees (without CyRPA protein) tested at 6, 3 or 1 mg/mL alone (red bars) or with addition of both of the anti-RIPR mAb pools (at a fixed total concentration of 2 mg/mL). Grey and blue bars indicate predicted and measured GIA as in panel B. Bars show mean, N = 2 independent replicates. D ) Cartoon summary of the proposed two-step mechanism for GIA mediated by anti-RIPR-Tail antibodies. left: the full P. falciparum PCRCR-complex binds to basigin-MCT1 complexes on the erythrocyte surface. Centre left: binding of anti-RIPR EGF (6-8) mAbs (orange) can lead to partial GIA. Centre right: anti-RIPR (9-10)-CTD mAbs (blue) or anti-CSS sdAbs (yellow) that block the RIPR-CSS binding interface are normally unable to access their epitopes and so invasion proceeds (no GIA). Right: Binding of anti-RIPR EGF (6-8) antibodies constrains RIPR-Tail conformational flexibility and disrupts the low affinity RIPR-CSS interaction. Exposure of the RIPR-CSS binding interface now enables binding of anti-RIPR (9-10)-CTD mAbs or anti-CSS sdAbs to their epitopes, thus blocking further RIPR-CSS interaction and synergistically enhancing GIA.
Candidate Malaria Vaccine, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/candidate malaria vaccine/product/Glaxo Smith
Average 86 stars, based on 1 article reviews
candidate malaria vaccine - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
malaria vaccine candidate increased several  (Menzel Inc)
86
Menzel Inc malaria vaccine candidate increased several
A) In vitro GIA against 3D7 clone P. falciparum using i) a pool of purified total IgG from <t>R78C/Matrix-M</t> healthy UK adult vaccinees tested at 6 mg/mL; ii) protein alone controls (CyRPA and RIPR) both at 5 µM; iii) a pool of anti-RIPR EGF (9-10)-CTD mAbs (RP.063, RP.064, RP.073 and RP.085) and a pool of anti-RIPR EGF (6) mAbs (RP.047 and RP.107), both at 1 mg/mL; and iv) combinations of test samples. B ) GIA of the purified total IgG from R78C vaccinees combined with CyRPA protein along with addition of either or both of the anti-RIPR mAb pools (all concentrations as in panel A). Grey bars show % GIA predicted by Bliss additivity (PBA) of the test combinations, and blue bars how the measured % GIA. C ) GIA of the purified total IgG from R78C vaccinees (without CyRPA protein) tested at 6, 3 or 1 mg/mL alone (red bars) or with addition of both of the anti-RIPR mAb pools (at a fixed total concentration of 2 mg/mL). Grey and blue bars indicate predicted and measured GIA as in panel B. Bars show mean, N = 2 independent replicates. D ) Cartoon summary of the proposed two-step mechanism for GIA mediated by anti-RIPR-Tail antibodies. left: the full P. falciparum PCRCR-complex binds to basigin-MCT1 complexes on the erythrocyte surface. Centre left: binding of anti-RIPR EGF (6-8) mAbs (orange) can lead to partial GIA. Centre right: anti-RIPR (9-10)-CTD mAbs (blue) or anti-CSS sdAbs (yellow) that block the RIPR-CSS binding interface are normally unable to access their epitopes and so invasion proceeds (no GIA). Right: Binding of anti-RIPR EGF (6-8) antibodies constrains RIPR-Tail conformational flexibility and disrupts the low affinity RIPR-CSS interaction. Exposure of the RIPR-CSS binding interface now enables binding of anti-RIPR (9-10)-CTD mAbs or anti-CSS sdAbs to their epitopes, thus blocking further RIPR-CSS interaction and synergistically enhancing GIA.
Malaria Vaccine Candidate Increased Several, supplied by Menzel Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/malaria vaccine candidate increased several/product/Menzel Inc
Average 86 stars, based on 1 article reviews
malaria vaccine candidate increased several - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
candidate malaria vaccine 257049 against malaria disease  (Glaxo Smith)
86
Glaxo Smith candidate malaria vaccine 257049 against malaria disease
A) In vitro GIA against 3D7 clone P. falciparum using i) a pool of purified total IgG from <t>R78C/Matrix-M</t> healthy UK adult vaccinees tested at 6 mg/mL; ii) protein alone controls (CyRPA and RIPR) both at 5 µM; iii) a pool of anti-RIPR EGF (9-10)-CTD mAbs (RP.063, RP.064, RP.073 and RP.085) and a pool of anti-RIPR EGF (6) mAbs (RP.047 and RP.107), both at 1 mg/mL; and iv) combinations of test samples. B ) GIA of the purified total IgG from R78C vaccinees combined with CyRPA protein along with addition of either or both of the anti-RIPR mAb pools (all concentrations as in panel A). Grey bars show % GIA predicted by Bliss additivity (PBA) of the test combinations, and blue bars how the measured % GIA. C ) GIA of the purified total IgG from R78C vaccinees (without CyRPA protein) tested at 6, 3 or 1 mg/mL alone (red bars) or with addition of both of the anti-RIPR mAb pools (at a fixed total concentration of 2 mg/mL). Grey and blue bars indicate predicted and measured GIA as in panel B. Bars show mean, N = 2 independent replicates. D ) Cartoon summary of the proposed two-step mechanism for GIA mediated by anti-RIPR-Tail antibodies. left: the full P. falciparum PCRCR-complex binds to basigin-MCT1 complexes on the erythrocyte surface. Centre left: binding of anti-RIPR EGF (6-8) mAbs (orange) can lead to partial GIA. Centre right: anti-RIPR (9-10)-CTD mAbs (blue) or anti-CSS sdAbs (yellow) that block the RIPR-CSS binding interface are normally unable to access their epitopes and so invasion proceeds (no GIA). Right: Binding of anti-RIPR EGF (6-8) antibodies constrains RIPR-Tail conformational flexibility and disrupts the low affinity RIPR-CSS interaction. Exposure of the RIPR-CSS binding interface now enables binding of anti-RIPR (9-10)-CTD mAbs or anti-CSS sdAbs to their epitopes, thus blocking further RIPR-CSS interaction and synergistically enhancing GIA.
Candidate Malaria Vaccine 257049 Against Malaria Disease, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/candidate malaria vaccine 257049 against malaria disease/product/Glaxo Smith
Average 86 stars, based on 1 article reviews
candidate malaria vaccine 257049 against malaria disease - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


A) In vitro GIA against 3D7 clone P. falciparum using i) a pool of purified total IgG from R78C/Matrix-M healthy UK adult vaccinees tested at 6 mg/mL; ii) protein alone controls (CyRPA and RIPR) both at 5 µM; iii) a pool of anti-RIPR EGF (9-10)-CTD mAbs (RP.063, RP.064, RP.073 and RP.085) and a pool of anti-RIPR EGF (6) mAbs (RP.047 and RP.107), both at 1 mg/mL; and iv) combinations of test samples. B ) GIA of the purified total IgG from R78C vaccinees combined with CyRPA protein along with addition of either or both of the anti-RIPR mAb pools (all concentrations as in panel A). Grey bars show % GIA predicted by Bliss additivity (PBA) of the test combinations, and blue bars how the measured % GIA. C ) GIA of the purified total IgG from R78C vaccinees (without CyRPA protein) tested at 6, 3 or 1 mg/mL alone (red bars) or with addition of both of the anti-RIPR mAb pools (at a fixed total concentration of 2 mg/mL). Grey and blue bars indicate predicted and measured GIA as in panel B. Bars show mean, N = 2 independent replicates. D ) Cartoon summary of the proposed two-step mechanism for GIA mediated by anti-RIPR-Tail antibodies. left: the full P. falciparum PCRCR-complex binds to basigin-MCT1 complexes on the erythrocyte surface. Centre left: binding of anti-RIPR EGF (6-8) mAbs (orange) can lead to partial GIA. Centre right: anti-RIPR (9-10)-CTD mAbs (blue) or anti-CSS sdAbs (yellow) that block the RIPR-CSS binding interface are normally unable to access their epitopes and so invasion proceeds (no GIA). Right: Binding of anti-RIPR EGF (6-8) antibodies constrains RIPR-Tail conformational flexibility and disrupts the low affinity RIPR-CSS interaction. Exposure of the RIPR-CSS binding interface now enables binding of anti-RIPR (9-10)-CTD mAbs or anti-CSS sdAbs to their epitopes, thus blocking further RIPR-CSS interaction and synergistically enhancing GIA.

Journal: bioRxiv

Article Title: Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR

doi: 10.64898/2025.12.16.693247

Figure Lengend Snippet: A) In vitro GIA against 3D7 clone P. falciparum using i) a pool of purified total IgG from R78C/Matrix-M healthy UK adult vaccinees tested at 6 mg/mL; ii) protein alone controls (CyRPA and RIPR) both at 5 µM; iii) a pool of anti-RIPR EGF (9-10)-CTD mAbs (RP.063, RP.064, RP.073 and RP.085) and a pool of anti-RIPR EGF (6) mAbs (RP.047 and RP.107), both at 1 mg/mL; and iv) combinations of test samples. B ) GIA of the purified total IgG from R78C vaccinees combined with CyRPA protein along with addition of either or both of the anti-RIPR mAb pools (all concentrations as in panel A). Grey bars show % GIA predicted by Bliss additivity (PBA) of the test combinations, and blue bars how the measured % GIA. C ) GIA of the purified total IgG from R78C vaccinees (without CyRPA protein) tested at 6, 3 or 1 mg/mL alone (red bars) or with addition of both of the anti-RIPR mAb pools (at a fixed total concentration of 2 mg/mL). Grey and blue bars indicate predicted and measured GIA as in panel B. Bars show mean, N = 2 independent replicates. D ) Cartoon summary of the proposed two-step mechanism for GIA mediated by anti-RIPR-Tail antibodies. left: the full P. falciparum PCRCR-complex binds to basigin-MCT1 complexes on the erythrocyte surface. Centre left: binding of anti-RIPR EGF (6-8) mAbs (orange) can lead to partial GIA. Centre right: anti-RIPR (9-10)-CTD mAbs (blue) or anti-CSS sdAbs (yellow) that block the RIPR-CSS binding interface are normally unable to access their epitopes and so invasion proceeds (no GIA). Right: Binding of anti-RIPR EGF (6-8) antibodies constrains RIPR-Tail conformational flexibility and disrupts the low affinity RIPR-CSS interaction. Exposure of the RIPR-CSS binding interface now enables binding of anti-RIPR (9-10)-CTD mAbs or anti-CSS sdAbs to their epitopes, thus blocking further RIPR-CSS interaction and synergistically enhancing GIA.

Article Snippet: The VAC089 trial is a non-randomised, open-label, first-in-human, Phase 1a trial of the blood-stage malaria candidate vaccine R78C, alone or in combination with RH5.1, formulated with Novavax’s Matrix-M® adjuvant.

Techniques: In Vitro, Purification, Concentration Assay, Binding Assay, Blocking Assay